The European Commission has given approval for BeiGene’s TEVIMBRA to be used as the initial treatment for advanced or metastatic esophageal squamous cell carcinoma and gastric or gastroesophageal junction cancer.

November 27, 2024

XLV Health Care
BGNE

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, today announced that the European Commission has approved…

Sector Investors News and Insights

The European Commission has given approval for BeiGene’s TEVIMBRA to be used as the initial treatment for advanced or metastatic esophageal squamous cell carcinoma and gastric or gastroesophageal junction cancer.

© 2024 ETF Sector

Sector Investors News and Insights

The European Commission has given approval for BeiGene’s TEVIMBRA to be used as the initial treatment for advanced or metastatic esophageal squamous cell carcinoma and gastric or gastroesophageal junction cancer.

© 2024 ETF Sector

Subscribe to our Newsletter